Methodology
How the edition was made: methods, the model card, the evidence cut and its age, the acceptance record and the glossary.
Contents
- ·Edition home
- ·Executive summary
- 1Synthetic biology is a build capability and a governance test
- 2Key findings
- 3Systems and sectors at baseline
- 4Risks and capability
- 5Design capability outpaces screening and oversight
- 6Readings from the other desks
- 7The 2027 agenda
- 8Systems in depth
- AMethodology
- A.1 Methods
- A.2 Model card, Synthetic biology System Model v0
- A.3 The baseline evidence cut
- A.4 Evidence age and coverage
- A.5 Evidence cards, two anchor sources
- A.6 Publication acceptance record
- A.7 Status words
- A.8 How the edition is made, released and corrected
- A.9 Glossary and abbreviations
- A.10 Technical annex
- BData appendix
- CReferences and record
- ·Complete edition, for print
A.1Methods
The global baseline uses published values and four simple derivations. Each is shown in full so that any reader can reproduce it.
| No. | Derivation | Calculation | Result |
|---|---|---|---|
| (1) | Fall in codons from the standard code to Syn57 | 64 minus 57 | 7 codons |
| (2) | Growth in recoded codons, Syn57 against Syn61 (lower bound) | 101,000 ÷ 18,214 | about 5.5 times |
| (3) | Change in Ginkgo Bioworks revenue, 2024 to 2025 | (170.155 minus 227.043) ÷ 227.043 | about minus 25% |
| (4) | Share of Twist Bioscience third-quarter revenue from DNA synthesis and protein solutions | 56.6 ÷ 118.4 | about 48% |
| Strength | Definition |
|---|---|
| STRONG | a disruption in the source system has historically changed the target system’s service or output within one season, in more than one region |
| MODERATE | an effect is documented but buffered or slower |
| WEAK | an effect is plausible but not documented at global scale |
| Label | Rule |
|---|---|
| Reported | value as issued by its source, with year |
| Inferred | reasoned from cited evidence; never a measurement |
| Estimated | Nexus analytical value with stated method |
| Scenario | conditional on stated assumptions |
| Expert input | structured editorial judgement awaiting evidence |
A.2Model card, Synthetic biology System Model v0
- Model ID
- MDL-XT04-SYNBIO · v0.1
- Purpose
- represent synthetic biology as a build capability and manufacturing base coupled to health, food, energy, feedstock, finance, workforce and biosecurity
- Family
- graph-based system of systems
- Inputs
- the cited sources of this edition; no proprietary data
- Method
- expert-specified coupling strengths (STRONG · MODERATE · WEAK) from assessments and analogue events
- Validation
- none yet, first validation against federation evidence in 2027
- Uncertainty
- qualitative; strengths are hypotheses, not measurements
- Domain of validity
- global scale; not for asset-, site- or country-level use
- Reproducibility
- strength table and sources published in this edition
20couplings
typed in v0
0strong
documented within one season
1moderate
documented, buffered
19weak
plausible, undocumented
A.3The baseline evidence cut
Every Nexus edition is published from a frozen evidence cut. The global baseline cut is documentary: it pins the exact edition of every source cited. Federation cuts begin with the first national Foundry cuts in 2027.
- Cut ID
- DC-XTECH-SYNBIO-GLOBAL-2026-B0
- Type
- baseline documentary cut
- Resolution policy
- pinned · as of 30 September 2026
- Sources pinned
- 44 cited sources, each at the edition and access date in the references
- Model runs
- none at baseline, analytical values are stated with their method
- Digest
- computed at freeze and recorded in the publication record
- Supersedes
- nothing, first cut of the series
- Superseded by
- the 2027 synthetic biology annual cut
Lineage
- 01
source edition
- 02
pinned citation
- 03
finding
- 04
page
- 05
publication record
| Element | Baseline 2026 | 2027 global annual |
|---|---|---|
| Sources | cited global publications, pinned by edition | national, regional and sector cuts through one graph |
| Analysis | stated methods and editorial estimates | typed analysis specifications |
| Models | Synthetic biology System Model v0 specification | model runs with receipts |
| Findings | twelve baseline findings | findings re-bound to federation evidence |
| Review | five passes scheduled | five passes on the exact digest |
A.4Evidence age and coverage
A 2026 global edition rests on evidence observed in many different years. This page shows each time base, so that no single year label hides older evidence.
| Indicator | Observed | Released | Cadence | Next release |
|---|---|---|---|---|
| Recoded genome results | 2019 to 2025 | Nature 2019 · Science Oct 2025 | one-off | follow-up papers |
| Synthetic yeast | 2023 | Cell Dec 2023 | one-off | completion papers |
| Screening study | 2025 | Science Oct 2025 | one-off | follow-up studies |
| US commission report | 2025 | Apr 2025 | one-off | legislation |
| US screening framework | 2024 · 2025 order | Apr 2024 · May 2025 | periodic | replacement text |
| EU Biotech Act | 2025 | Dec 2025 | periodic | second act |
| OECD governance paper | 2026 | May 2026 | one-off | next policy paper |
| Company results | 2025 to 2026 | Feb 2026 · Aug 2026 | quarterly | next earnings |
| System | Coverage | Thinnest dimension |
|---|---|---|
| Build capability | GOOD | industrial-scale performance |
| Clinical | PARTIAL | long-term outcomes |
| Biosecurity | PARTIAL | screening coverage |
| Governance | PARTIAL | text of replacement US framework |
| Investment | THIN | common basis for public and private |
| Energy and feedstock | THIN | fermentation footprint |
| Capacity | THIN | biofoundry and plant counts |
| Skills | THIN | workforce numbers |
| Field | Source that would fill it | Blocker |
|---|---|---|
| Energy, water and feedstock use of biomanufacturing at scale | producers, national laboratories, peer-reviewed life-cycle studies | not retrieved on a common basis; no study opened |
| DNA synthesis capacity and screening coverage by provider and country | providers, industry consortia, national agencies | no consolidated series found; screening pages not opened |
| Status and text of the US screening framework after the 2025 order | OSTP and White House publications2526 | a fetch of the framework page was refused by the tool; status taken from search summaries and a CRS note summary27 |
| European Commission text of the Biotech Act proposal | European Commission proposal COM(2025) 102228 | primary page not retrieved; content taken from a law firm summary22 |
| Status of the EU second Biotech Act | European Commission, European Parliament legislative train29 | the page returned no content; timing is a Q3 2026 expectation from summaries |
| Public and private investment in synthetic biology on one basis | national statistics, OECD, industry surveys | not retrieved; only two company filings used1617 |
| Biofoundry and fermentation capacity by country | industry and trade statistics | not retrieved |
| Programme totals for the US distributed bioindustrial manufacturing awards after September 2024 | US manufacturing programme pages24 | the page read lists totals to September 2024 only |
| Bioeconomy size from a primary statistical source | national accounts, OECD | only a secondary commentary figure read15 |
| Workforce size and skills gaps | national statistics, OECD, industry surveys | not retrieved; capability rung stays LISTED |
| Independent replication and viral-resistance tests of recoded strains | peer-reviewed papers | not found at evidence close |
| Long-term outcomes of engineered therapies | trial follow-up publications | only the cited trial and one case report read810 |
| Mirror life risk assessment beyond the policy forum | peer-reviewed risk studies | only the forum abstract read12 |
| Capability rungs beyond guidance and planning | agencies, operators, laboratories | not reviewed |
A.5Evidence cards, two anchor sources
Published in Science 390 (2025) by Robertson and colleagues; news page of 1 August 2025. One-off. Role: binds BLD-001. Coverage: one organism in one laboratory line.
EVD-XT04-001
Escherichia coli with a 57-codon genetic code1
Published in Science 390 (2025). One-off study. Role: binds SEC-005. Coverage: screening tools and open design software; no sequence detail is reproduced here.
EVD-XT04-002
Strengthening nucleic acid biosecurity screening against generative protein design tools13
| Dimension | EVD-XT04-001 | EVD-XT04-002 |
|---|---|---|
| Completeness | one organism; about 4 million base pairs | a set of screening tools and design software |
| Timeliness | news page about 12 weeks before the journal date | journal publication in 2025 |
| Revision | preprint and journal versions | patches reported after testing |
| Method transparency | methods published in the paper | details limited for security reasons |
| External validation | peer review | peer review |
Evidence cards to follow in 2027
A.6Publication acceptance record
Editorial self-check at evidence close. Every applicable item carries a disposition; the remaining items are review, approval and deposit.
| Group | Area | Items | Pass | N/A | Pending |
|---|---|---|---|---|---|
| D1 | Identity and scope | 8 | 8 | 0 | 0 |
| D2 | Source and data | 12 | 9 | 1 | 2 |
| D3 | Analysis and models | 12 | 3 | 8 | 1 |
| D4 | Findings and claims | 9 | 8 | 0 | 1 |
| D5 | Figures, tables, maps | 10 | 6 | 2 | 2 |
| D6 | Editorial and citations | 10 | 8 | 0 | 2 |
| D7 | Review and approval | 13 | 0 | 0 | 13 |
| D8 | Artefact and design | 12 | 7 | 0 | 5 |
| D9 | Registry and release | 9 | 0 | 0 | 9 |
Publication gate
- Conditions met
- 14 of 23 at evidence close
- Blocking problems
- none recorded
- Open conditions
- reviews, approval of the exact digest, deposit, registry pointer
Not applicable at baseline
- Model runs
- first runs in Q1 2027
- Maps
- plates in Q2 2027
- Waivers
- none
A.7Status words
| Status | What it means |
|---|---|
| Observed | Measured directly and published by the source. |
| Reported | Published statistics of an official or institutional source. |
| Declared | Stated by the body concerned; not independently measured. |
| Estimated | A Nexus estimate from cited evidence, with its method in Annex A. |
| Modelled | Produced by a stated model from cited inputs. |
| Inferred | Reasoned from cited evidence; not measured. |
| Forecast | A projection by the cited source. |
| Simulated | A simulation result under stated assumptions. |
| Scenario | A conditional statement under stated assumptions; never a prediction. |
| Expert input | Expert judgement, recorded with its basis. |
| Candidate | Proposed for a later edition; not yet evidence. |
| Evidence-quality levels (EQL 1 to 5) grade the source behind a value; they are not a score of the subject. | |
A.8How the edition is made, released and corrected
Every edition is built from a sealed evidence cut, reviewed under three keys, signed and deposited before any site shows it as published; corrections go to Nexus Standards as change proposals and feed the next cut.
| Step | What happens | Source |
|---|---|---|
| 01 Evidence arrives from the pillars | Foundry seals observations and indicator series, Universe hands over after-action and scenario findings, and contributions are screened at every gateway, including this site’s. | |
| 02 The cut is sealed | On the cut date the evidence is pinned under one identifier, so anyone can rebuild the edition from exactly what it was built on. | |
| 03 The edition is assembled | The edition is drafted from its template and content pack. Agents may draft; they never publish and never decide. | |
| 04 The keys turn | At the publisher of record the truth key comes first: every value is checked against its source or stated method before the meaning and capital keys turn. No edition moves on until every key has been turned by a named steward. | |
| 05 The gate opens | A named approver releases one exact digest of the edition; any change after this point is a new version, never a silent edit. | |
| 06 Signed and deposited | The PDF, the web edition and the data bundle are signed together with a manifest and an RO-Crate description, and deposited on Zenodo with a concept and a version DOI. | |
| 07 Published on its desk’s site | Only then does the edition show as published on its desk’s Reports site, and the Collection lists it as a part. | |
| 08 Corrections go to Standards | Method and correction findings go to Nexus Standards as change proposals; citations, corrections and new contributions feed the next evidence cut. |
A teaching model of the process, not a forecast and not a record of any run; dates and counts on this page come from the programme record. Sources: Reports governance at GCRI Canada (2026); Zenodo, repository of record for Reports deposits (2026).
Lifecycle, one state at a time: Draft, Computed, Evidence bound, Reviewed, Approved for release, Published, Corrected, Superseded. This edition is a draft.
A.9Glossary and abbreviations
| Term | Meaning |
|---|---|
| Baseline Edition | the inaugural annual edition that fixes the reference state for the series |
| WEFH+B | water, energy, food, health and biodiversity, the national nexus core |
| Coupling | a typed dependency through which one system transmits to another |
| Protection gap | the share of losses not covered by insurance |
| Capability ladder | LISTED → EXISTS → ADEQUATE → TESTED → DEMONSTRATED |
| EQL | evidence-quality level, 1–5 |
| Evidence cut | a frozen resolution of exact sources and versions |
| NNC · NLC · NWG | National Nexus Consortium · National Leadership Council · National Working Groups |
| Abbreviation | Expansion |
|---|---|
| AHTEG | Ad Hoc Technical Expert Group |
| BWC | Biological Weapons Convention |
| CBD | Convention on Biological Diversity |
| CRS | Congressional Research Service |
| DBIMP | Distributed Bioindustrial Manufacturing Program |
| EO | executive order |
| FDA | US Food and Drug Administration |
| IGSC | International Gene Synthesis Consortium |
| NSCEB | National Security Commission on Emerging Biotechnology |
| OECD | Organisation for Economic Co-operation and Development |
| OSTP | Office of Science and Technology Policy |
| SPC | supplementary protection certificate |
A.10Technical annex
| Item | Annex | Contents | Status |
|---|---|---|---|
| A.1 | Indicator definitions | the global indicator set, with units and sources | IN THIS EDITION |
| A.2 | Coupling strengths | the twenty-cell matrix and its rationale | IN THIS EDITION |
| A.3 | Scenario specification | SCN-XT04-DSG-01 assumptions and signposts | IN THIS EDITION |
| A.4 | Capability placements | rung evidence for fifteen functions | IN THIS EDITION |
| A.5 | Model diagnostics | first runs and validation | 2027 |
| A.6 | Sensitivity analyses | influence of coupling strengths | 2027 |
| A.7 | Cluster notes | cards for the major platform, DNA supply and manufacturing clusters | 2027 |
| A.8 | Review statements | pass-by-pass review record | AT RELEASE |
A.1 · indicator definition: codons recoded
- Construct
- number of codon positions in a genome replaced by a synonymous codon
- Unit
- count of codons
- Method
- genome design, fragment synthesis and assembly
- Source
- Nature 569 (2019)3; Science 390 (2025) and the research institute news page2
- Uncertainty
- the Syn57 count is stated as over 101,000, a lower bound
- Known limits
- counts may include sense codons and a stop codon; one lineage of organisms
Notes
Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references
- 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.back
- 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
- 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back
- 28UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.back
- 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
- 29UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.back
- 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
- 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
- 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
- 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
- 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
- 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
- 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
- 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
- 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back